Now recruiting patients with ulcers for a study supported by NHS England

Contact us if your ulcer is less than 6 weeks old and you live in South-East England

Goal is to determine patient and economic benefits of using Acapsil as first-line treatment at GP-surgeries. Acapsil is already approved and available for sale over-the-counter.

To participate, your venous leg ulcers or diabetic foot ulcers must be less than 6 weeks old.
You must live in Hampshire, East Dorset, West Surrey, Berkshire or the western part of West Sussex.

Goal is to determine patient and economic benefits of using Acapsil as first-line treatment at GP-surgeries. Acapsil is already approved and available for sale over-the-counter.

To participate, your ulcers must be less than 6 weeks old.
You must live in Hampshire, East Dorset, West Surrey, Berkshire or the western part of West Sussex.

60% quicker
than antibiotics

at removing infection

at removing infection

at removing infection

Passive Immunotherapy

Acting via the skin microbiome

Acting via the skin microbiome

Acting via the skin microbiome

Removes pain,
smell and discharge

by efficiently removing the infection

by efficiently removing the infection

by efficiently removing the infection

Less Scarring

"Where I have used Acapsil the scarring is flat, whereas the older scars are hypertrophic." ST

"Where I have used Acapsil the scarring is flat against the surrounding skin, whereas the older scars are bulging / hypertrophic." ST

"Where I have used Acapsil the scarring is flat against the surrounding skin, whereas the older scars are bulging / hypertrophic." ST

"Acapsil changed my life."

"From 4 weeks of absolute hell - to being pain-free, getting a full night's sleep and back to normal at work."

"From 4 weeks of absolute hell, in pain 24 hours a day, struggling at work - to being pain-free, getting a full night's sleep and back to normal at work."

"From 4 weeks of absolute hell, in pain 24 hours a day, struggling at work - to being pain-free, getting a full night's sleep and back to normal at work."

NH ( patient)

NH ( patient)

NH ( patient)

Did you know:
killing the microbes in your wound makes YOU resistant!

MPPT removes infection without killing

MPPT removes infection without killing

MPPT removes infection without killing

69.5% Savings

Cost-effectiveness determined in NHS Clinical Audit

Cost-effectiveness determined in NHS Clinical Audit

Cost-effectiveness determined in NHS Clinical Audit

Hypoallergenic

Only natural ingredients

Only natural ingredients

Only natural ingredients

FDA Executive Review:

Antibiotic and antiseptic dressings do not improve wound infections or wound healing.

Antibiotic and antiseptic dressings do not improve wound infections or wound healing.

Antibiotic and antiseptic dressings do not improve wound infections or wound healing.

US FDA 2016

US FDA 2016

US FDA 2016

In connection with publication on MPPT, the

In connection with publication on MPPT, the

In connection with publication on MPPT, the

Chair of WHO Anti-Microbial-Resistance group said:

“AMR is an escalating global threat. We need alternative treatments, including innovative ways to use the body’s own immune system and healthy bacteria.”

“AMR is an escalating global threat. We need alternative treatments, including innovative ways to use the body’s own immune system and healthy bacteria.”

“AMR is an escalating global threat. We need alternative treatments, including innovative ways to use the body’s own immune system and healthy bacteria.”

“For me, this Acapsil open air method is a no brainer. It is easier, no fuss, and obviously cheaper than these expensive dressings.”

VH (patient)

VH (patient)

VH (patient)

previous arrow
next arrow
Slider

As a healthcare company, Willingsford focuses on the healing of complicated wounds. Experience has repeatedly shown that what sounds ingenious as a theory on the drawing board or looks very promising in the artificially controlled environment of the laboratory does not always turn out to perform as remarkably as hoped for once transferred into the real life environment. Underlying diseases as well as non-artificially created situations and injuries heavily affect the outcome of the recovery processes. Therefore, in Willingsford, we focus on what works in patients in real life.

We do all our research in accordance with the principles of the pharmaceutical industry and, of course, our development is done to the highest standards of the industry. We only settle for products that show substantial benefits to patients.

We know what we do best and focus on that. Consequently, we are only interested in truly novel solutions or therapies that provide real therapeutical improvements. For the same reasons, we do not pursue the development of follow-on products nor do we try to create an artificial need.

This approach may not help us grow into the biggest commercial healthcare company in the world. We believe, however, that keeping this focus, will allow us to retain a high degree of overall company agility and quick decision making which, again, will allow us to create the right environment for doing what we are good at, namely Challenge dogmas, Interpret & trust data, Innovate and Create change.

Close Menu
Close Panel